Loading...
Market
Which region in the US will have the highest adoption rate of the FluMist nasal spray in the 2024-2025 flu season?
2
Resolution / Starting Odds
Northeast • 25%
South • 25%
Midwest • 25%
West • 25%
Regional sales data from AstraZeneca and pharmacy chains
Story
FDA Approves First-of-Its-Kind FluMist Nasal Spray for Self-Administration
Sep 20, 2024, 08:15 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self-administration, making it the first of its kind. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. The FluMist vaccine, which contains a weakened live virus, is designed for individuals aged 2 to 49 and covers influenza virus subtypes A and B. This development is part of a broader effort by the FDA to expand consumer access to medicines and reduce healthcare costs and barriers. The vaccine will be available through a third-party pharmacy, where individuals will complete a screening and eligibility assessment before ordering. The FluMist nasal spray will be available starting next season.
View original story
Similar markets
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
California • 25%
Texas • 25%
Florida • 25%
New York • 25%
2-18 years • 25%
19-29 years • 25%
30-49 years • 25%
All age groups equally • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
2-12 years • 25%
13-24 years • 25%
25-35 years • 25%
36-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
California • 25%
Texas • 25%
Iowa • 25%
Other • 25%
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%